Eptotermin alfa

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEptotermin alfa
Drug Alias Nameeptotermine alfa依奥特明α依托特明αEptotermin alphaEptotermin α +[16] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionBone morphogenetic protein receptor type-1B stimulantsBone morphogenetic protein receptor type-2 agonistsBone morphogenetic protein receptor type-1A stimulants
TargetsBone morphogenetic protein receptor type-1ABone morphogenetic protein receptor type-2Bone morphogenetic protein receptor type-1B
Therapy Area/IndicationsTibial FracturesOsteoarthritis, KneeSpondylolisthesis
Global Approved IndicationsTibial Fractures
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2001/05/17
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesCuris Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKnight TherapeuticsOlympus Biotech International LtdStryker Biotech
Active IndicationsN/A
Inactive IndicationsTibial FracturesOsteoarthritis, KneeSpondylolisthesis

Other Information

ATC CodeM05BC02
Related LinksKEGG